Clinical trial

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

NCT05063734

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-08-27

PhasePHASE2

Study timeline

Study start (actual)2021-08-27Date precision: day

Registry last updated2023-08-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitusunresolved

Diabetic Retinopathyunresolved

Diabetic Macular Edemaunresolved

Interventions

THR-687 dose level 1DRUG

THR-687 dose level 2DRUG

THR-687 selected dose levelDRUG

AfliberceptDRUG · verified · RxNorm: aflibercept

Sponsors & collaborators

Oxurionlead sponsor

Mapped research locations

RigaLatvia2 TallinnEstonia2 San AntonioTexas, United States1 NashvilleTennessee, United States1 AustinTexas, United States1 SacramentoCalifornia, United States1 TulsaOklahoma, United States1 Colorado SpringsColorado, United States1 RenoNevada, United States1 PasadenaCalifornia, United States1 PécsHungary1 SzegedHungary1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05063734 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.